以整合素为靶点的抗肿瘤药物研究进展

Drug Development in Anti-tumor Therapy by Targeting of Integrin

整合素作为一类具有信号转导功能的细胞表面粘附分子,与肿瘤的发生、发展密切相关。整合素能与细胞内多种分子相互协调,从多方面影响肿瘤的增殖、侵袭和转移等过程。以整合素为靶点进行的抗肿瘤药物的研发及相应治疗方法的开发已成为当前肿瘤治疗的热点。该文从整合素抗体类药物,含RGD等与整合素高亲和力结合序列的药物以及其他整合素靶向药物3方面综述了近年来以整合素为靶点的抗肿瘤药物研究开发的最新进展,并对整合素的靶向治疗进行了探讨。

As a kind of cell surface adhesion molecule which also has signal transduction functions, integrin plays a vital role in many aspects of tumor progression. Integrin can cooperate signaling with many cellular molecules and regulates tumor cell growth, invasion and metastasis. The research using integrins as targets on anti-tumor drug design and the corresponding treatment strategy has been a hotpoint in recent years. This review focuses on the latest developments in anti-tumor drug design which includes antibodies against integrin, molecules with high affinity integrin-binding motifs and other kinds of integrin-targeting drugs, and further discusses the integrin-targeting treatments in the field of cancer research.